Multiple Patents Granted and Pipeline of Ophthalmic Drug Candidates

We are advancing a pipeline of wholly-owned candidates that address a number of diseases with high unmet need from front of eye conditions to back of eye conditions. The lead project is CBT-001 for the treatment of pterygium.

*Prevalence varies from region to region, and is heavily dependent on demographics and environmental conditions.

ARMD, age-related macular degeneration; DME, diabetic macular edema.

1. Shahraki T, et al. Ther Adv Ophthalmol. 2021;13:25158414211020152. 2. Rezvan F, et al. Surv Ophthalmol. 2018;63(5):719-735. 3. Grzybowski A, et al. BMC Ophthalmol. 2020;20(1):27. 4. Arenas E, et al. Pan Am J Ophthalmol. 2019;1(1):9. 5. Hassanzadeh S, et al. Ocular Immunol Inflamm. 2020;29(1):66-75. 6. Fricke TR, et al. Ophthalmology. 2018;125(10):1492-1499. 7. Tham Y-C, et al. Ophthalmology. 2014;121(11):2081-290. 8. Yan P, et al. Invest Ophthalmol Vis Sci. 2021;62(8):1143. 9. Wong WL, et al. Lancet Glob Health. 2014;2(2):e106-e116.